Zentiva Announces the Acquisition of Creo Pharmaceuticals Ltd. in the UK

Prague (ots/PRNewswire) - Zentiva Group a.s. is announcing the
acquisition of Creo Pharmaceuticals Ltd. in the UK, a subsidiary of
Amneal Pharmaceuticals, Inc. (NYSE: AMRX).

Nick Haggar, CEO of Zentiva stated: "Zentiva is delighted to
confirm the acquisition of Creo Pharma which will strengthen
Zentiva's position in the UK. This move reflects our confidence in
the UK and our deep commitment to the development, manufacture and
supply of high-quality affordable medicines. We welcome the Creo
Pharma team who have a strong reputation for providing high-quality
services to their customers."

"We are happy to join Zentiva as we are convinced that the
combination of our two businesses will bring value to our customers
and to patients in the UK. We believe the combination of Creo and
Zentiva will allow us to accelerate our growth and achieve our full
potential," said Luke Hart, Managing Director of Creo Pharmaceuticals
Ltd.

About Zentiva
Zentiva is a European producer of high-quality medicines serving
patients in Europe, the Middle East and Africa. With a dedicated team
of more than 2,500 people and our network of production sites -
including our flagship sites in Prague and Bucharest - we strive to
be the champions of branded and generic medicines in Europe to better
support peoples' daily healthcare needs.

At Zentiva it is our aspiration that healthcare should be a right and
not a privilege. More than ever, people need better access to high
quality affordable medicines and healthcare. We work in partnership
with physicians, pharmacists, wholesalers, regulators and governments
to provide the everyday solutions that we all depend on.

About Creo Pharmaceuticals Ltd.
Creo Pharma was established in 2007 to provide supply partners with
direct marketing access in the UK generics market. We are a
reputable, reliable and expanding UK pharmaceutical provider with a
key focus on supplying the wholesale, pharmacy and hospital sectors
with everything from generic medicines to commercial brands. Creo's
success is built upon strong customer relationships, exceptional
support and a diverse product portfolio. We understand that trust and
reliability are vital requirements for today's fast-paced generics
environment and fulfil these demands with a friendly, professional
customer service team. Our core aims are centred around our customers
priorities, ensuring medical professionals and patients alike have
access to a host of unique products.

Media Contact:
Ines Windisch
Head of Corporate Affairs & Human Resources

ZENTIVA GROUP, a.s.
U Kabelovny 130 - 102 37 Prague 10 - Czech Republic
Cell: +420-601-341-444
E-mail: ines.windisch@zentiva.com
www.zentiva.com

Logo:
https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpgLogo:
https://mma.prnewswire.com/media/843652/creo_Logo.jpg

ots Originaltext: Zentiva
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Zentiva, übermittelt durch news aktuell